Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%

By Reuters News

Oct 23 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK & CO INC: INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED THE RISK OF RECURRENCE OR DEATH BY 42% COMPARED TO KEYTRUDA ALONE

  • MERCK & CO: SAFETY PROFILE OF INTISMERAN PLUS KEYTRUDA WAS GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF COMBINATION

  • MERCK: INTISMERAN PLUS KEYTRUDA REDUCED RISK OF RECURRENCE OR DEATH BY 58% COMPARED TO KEYTRUDA ALONE

  • MERCK & CO: IN PHASE 3 INTERPATH-001 TRIAL NO NEW SAFETY SIGNALS WERE OBSERVED

  • MERCK: OVERALL SURVIVAL DATA ARE NOT YET MATURE, BUT FAVORABLE TREND IN OS WITH INTISMERAN PLUS KEYTRUDA HAS BEEN OBSERVED

  • MERCK: INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED RISK OF DISTANT METASTASIS OR DEATH BY 38% VERSUS KEYTRUDA ALONE

  • MERCK: INTISMERAN PLUS KEYTRUDA REDUCED RECURRENCE/DEATH RISK BY 58%, REDUCED RISK OF DISTANT METASTASIS/DEATH BY HALF AT 6 MONTHS VERSUS KEYTRUDA ALONE

Further company coverage: MRK.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.